Want to see IN:ALKEM full AI Analyst Report?
ALKEM Stock Chart & Stats
₹5558.15
-₹65.00(-1.17%)
At close: 4:00 PM EST
₹5558.15
-₹65.00(-1.17%)
Day’s Range― - ―
52-Week Range₹5,085.00 - ₹5,933.00
Previous CloseN/A
Volume39.00K
Average Volume (3M)25.41K
Market Cap
₹620.78B
Enterprise Value₹615.38K
Total Cash (Recent Filing)₹40.61B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)28.8
Beta0.57
Next Earnings
Nov 06, 2026EPS Estimate
58.85Next Dividend Ex-DateN/A
Dividend Yield1.02%
Share Statistics
EPS (TTM)180.25
Shares Outstanding119,565,000
10 Day Avg. Volume22,257
30 Day Avg. Volume25,414
Financial Highlights & Ratios
PEG Ratio4.33
Price to Book (P/B)4.54
Price to Sales (P/S)4.26
P/FCF Ratio46.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹6,250.00Price Target Upside12.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)194.11
Revenue Forecast (FY)₹166.76B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue expansion indicates continuing demand for Alkem’s branded generics and pharmaceutical products. Growth across domestic and international channels can strengthen operating scale and support durable earnings capacity.
Conservative Balance SheetLow leverage and a growing equity base provide financial flexibility for product development, manufacturing investment and market expansion. The conservative balance sheet also reduces refinancing risk and supports resilience through industry cycles.
Solid ProfitabilityHealthy margins and rising net income demonstrate that Alkem converts pharmaceutical demand into attractive profits. This supports internal funding for growth and indicates strength in its branded-generics manufacturing and distribution model.
Bears Say
Weak Cash ConversionWeak conversion of reported earnings into cash may reflect working-capital needs or reinvestment demands. If persistent, it could limit funds available for capacity expansion, acquisitions, debt reduction or shareholder returns.
Margin VolatilityMargin variability makes future earnings less predictable and may indicate exposure to product mix, pricing, input costs or competitive pressure. Sustained consistency will be important for demonstrating durable pharmaceutical profitability.
Earnings Growth PressureA decline in per-share earnings while revenue grows suggests that cost, margin or share-base pressures are absorbing part of the company’s expansion. Continued divergence could weaken the quality and sustainability of earnings growth.
Alkem Laboratories Ltd. News
ALKEM FAQ
What was Alkem Laboratories Ltd.’s price range in the past 12 months?
Alkem Laboratories Ltd. lowest stock price was ₹5085.00 and its highest was ₹5933.00 in the past 12 months.
What is Alkem Laboratories Ltd.’s market cap?
Alkem Laboratories Ltd.’s market cap is ₹620.78B.
When is Alkem Laboratories Ltd.’s upcoming earnings report date?
Alkem Laboratories Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 60 days.
How were Alkem Laboratories Ltd.’s earnings last quarter?
Alkem Laboratories Ltd. released its earnings results on Aug 14, 2026. The company reported ₹43.5 earnings per share for the quarter, missing the consensus estimate of ₹47.044 by -₹3.544.
Is Alkem Laboratories Ltd. overvalued?
According to Wall Street analysts Alkem Laboratories Ltd.’s price is currently Undervalued.
Does Alkem Laboratories Ltd. pay dividends?
Alkem Laboratories Ltd. pays a Semiannually dividend of ₹10 which represents an annual dividend yield of 1.02%. See more information on Alkem Laboratories Ltd. dividends here
What is Alkem Laboratories Ltd.’s EPS estimate?
Alkem Laboratories Ltd.’s EPS estimate is 58.85.
How many shares outstanding does Alkem Laboratories Ltd. have?
Alkem Laboratories Ltd. has 119,565,000 shares outstanding.
What happened to Alkem Laboratories Ltd.’s price movement after its last earnings report?
Alkem Laboratories Ltd. reported an EPS of ₹43.5 in its last earnings report, missing expectations of ₹47.044. Following the earnings report the stock price went down -0.364%.
Which hedge fund is a major shareholder of Alkem Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ALKEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alkem Laboratories Ltd.
Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and nutraceuticals. These products target both immediate and chronic health issues across numerous therapeutic areas, including anti-infectives, skin conditions, cardiovascular health, respiratory ailments, digestive problems, central nervous system disorders, cancer, urology, and women's health. The company also provides essential vitamins, minerals, and nutritional supplements, in addition to pain relief medications, anti-diabetic treatments, and neurological remedies. Complementing its core pharmaceutical lines, Alkem offers consumer health items such as pregnancy detection kits and condoms. Founded in 1973, the company's headquarters are located in Mumbai, India.
ALKEM Stock 12 Month Forecast
Average Price Target
₹6,250.00
▲(12.45% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Mankind Pharma Ltd.
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―